11 May 2020
ALLIANCE PHARMA PLC
(“Alliance” or the “Group”)
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that it has received notice that on 7 May 2020, Peter Butterfield, Chief Executive Officer of Alliance, exercised unapproved share options over 200,000 Ordinary Shares of 1p each in the Company (“Ordinary Shares”) under the Company’s Share Option Plans. The exercise price was 47.5 pence per share.
Following the exercise, Mr Butterfield retained 38,085 Ordinary Shares. Mr Butterfield sold 161,915 Ordinary Shares at a price of 74.7 pence per share to cover the associated exercise costs and tax liability arising on the exercise of the options. Following these transactions, Mr Butterfield’s total beneficial interest in the Group is 412,461 Ordinary Shares, representing approximately 0.08 per cent. of the Group’s issued share capital.
The 200,000 Ordinary Shares will be admitted to trading pursuant to an existing block listing and will rank pari passu with the existing Ordinary Shares in issue.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
Details of the person discharging managerial responsibilities/person closely associated
Reason for the notification
Chief Executive Officer
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
ALLIANCE PHARMA PLC
Legal Entity Identifier
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary shares of 1 pence each
Nature of the transaction
a) Exercise of options
b) Sale of Ordinary Shares
Price(s) and volume(s)
a) 47.5 pence
b) 74.7 pence
– Aggregated volume
– Aggregated total
Date of the transaction(s)
7 May 2020
Place of the transaction
London Stock Exchange, AIM
For further information:
Alliance Pharma plc
+ 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
Numis Securities Limited
+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Huw Jeremy
Corporate Broking: James Black
Investec Bank plc
+ 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.
We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com